Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| What we’ve seen thus far in ARC-20 has given us confidence that our molecule has a superior profile to that of belzutifan |
| Second, with an overall response rate of 21.9% in LITESPARK-005, we believe there is room for improvement |
| But I think by the time the big take home message is by the time you see these three data sets combined, I think it’s going to read very positively on adenosine modulation as a mechanism that has a meaningful role, particularly in the context of immunogenic chemotherapy as a standard of care where there’s headroom for improvement |
| With $1.2 billion in cash and equivalents in runway into 2027, we’re well positioned to deliver on the promise of the late-stage pipeline that we’ve built |
| We are also seeing signs of Cas’s ability to bring even aggressive tumor growth under control |
| PK profile and safety profile look really good |
| We believe that by hitting the HIF-2alpha target harder than Merck’s belzutifan, we can improve outcomes for patients |
| And we feel like very well positioned to execute on those trials |
| So, we feel we’re going to end up better than Belz, and it’s – there’s not going to be commodity here |
| So with dom’s potentially best-in-class profile, its optimized dosing regimen, as well as a broad development program focused on lung and gastric cancers, we’re really in a very strong competitive position |
| In summary, we are very encouraged by these early dose escalation and expansion cohort data, which, while early, have provided an encouraging signal that Cas’s PK/PD profile could translate into greater efficacy in the clinic |
| As Terry outlined earlier, Arcus continues to be in a very strong financial position |
| In summary, these data show exactly what we have been predicting, that Cas has a best-in-class PK/PD profile which should result in hitting the target harder and potentially in greater clinical activity relative to belzutifan |
| And importantly, with no other Phase 3 trials ongoing with the anti-TIGIT antibodies in this setting, we expect to have a significant first-to-market advantage |
| So we’ll have both of those under our belt, but we feel very good about our ability to enroll |
| With Gilead’s equity investment in January, we had approximately $1.2 billion of cash on hand and we’re really well capitalized to support the breadth of programs that we are pursuing |
| While these results are absolutely encouraging, the study reveals multiple opportunities for a new agent to prove upon Belzutifan’s profile and provide even more benefit to patients |
| The way things are looking, if you played around with the numbers, it looks like at least at the outset, that we’re doing perhaps better than that, and we’ll see how that plays out |
| And so that just becomes a marker for how hard are you hitting this thing? And then the fact that we can go 5x, what you can get out of the Merck molecule is what makes us feel good about hitting the tumor harder |
| We’ve already had a first ad Board meeting, and the enthusiasm for both HIF-2 as a general mechanism from what investigators have seen with Belz, as well as their anecdotal experience, which is now starting to get to be substantial with Cas, makes the field very exciting |
| These data demonstrated impressive six-month landmark PFS rates of 93% in PD-L1 high patients and 77% overall |
| But we believe that Cas has a best-in-class profile, and that’s addressing a very well recognized limitation of belzutifan |
| So we’re very excited about that molecule |
| We also have some exciting data sets come in the first half of this year for another molecule, and these really are exciting |
| We’ve got seven molecules in clinical development, a broad late-stage portfolio, multiple mid-stage clinical trials, a robust discovery engine, and now something I think new, a line of sight to commercialization |
| Our trials are focused on huge markets by any standard, lung and GI cancer, pancreatic cancer and RCC, where we’re extremely well positioned to compete with potential first-to-market or best-in-class therapies |
| So we do feel that STAR-121 best addresses that population with the best opportunity to become the standard of care for all comers |
| A first-line trial is an interesting market opportunity |
| We also continue to build for the long-term with a broad pipeline of potential best-in-class and first-in-class product candidates that will continue to replenish organically with our drug discovery engine |
| The time on treatment is impressive for these patients in very late-line setting, ranging from 8.5 to 14.5 months, and two of the four patients still remain on treatment |
| Statement |
|---|
| And certainly on those initial 30 patients, nothing that we’ve seen to-date has caused us concern |
| And so when you have CD155 engaging that CD226, you’re losing part of what you might otherwise gain |
| So we think that that’s going to further cannibalize that particular approach to treating that population |
| The clinical trial landscape for PD-L1 high lung has also become increasingly crowded with several anti-TIGIT and other investigational therapies, and we were not expected to be first or second in the PD-L1 high chemo free setting |
| And I think it’s very fair to say without these partnerships and the resources that these companies provide, we would not be able to execute on everything that we’re doing |
| At the highest level, CD155 is a bad thing |
| But the first group of patients are seeing some pretty significant reductions |
| For this reason, we expect Cas’s safety profile to be manageable and not meaningfully different than Belzutifan |
| And basically, that’s been very manageable |
| So hitting the target harder at the outset may be driving kinetics that are known to be not particularly fast |
| Although we have seen a couple of later patients having dramatic tumor reduction after multiple scans |
| The primary progression rate, which was relatively high, was a thing that stuck out for them |
Please consider a small donation if you think this website provides you with relevant information